These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1314 related articles for article (PubMed ID: 31718669)
21. Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years. Matsuda KI; Sakurada K; Nemoto K; Kayama T; Sonoda Y Int J Clin Oncol; 2018 Oct; 23(5):820-825. PubMed ID: 29796740 [TBL] [Abstract][Full Text] [Related]
22. Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma. Uto M; Mizowaki T; Ogura K; Arakawa Y; Mineharu Y; Miyamoto S; Hiraoka M Int J Clin Oncol; 2016 Dec; 21(6):1023-1029. PubMed ID: 27384182 [TBL] [Abstract][Full Text] [Related]
23. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985 [TBL] [Abstract][Full Text] [Related]
24. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084 [TBL] [Abstract][Full Text] [Related]
25. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196 [TBL] [Abstract][Full Text] [Related]
26. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821 [TBL] [Abstract][Full Text] [Related]
27. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R; Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848 [TBL] [Abstract][Full Text] [Related]
28. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. Terasaki M; Eto T; Nakashima S; Okada Y; Ogo E; Sugita Y; Tokutomi T; Shigemori M J Neurooncol; 2011 Apr; 102(2):247-53. PubMed ID: 20640480 [TBL] [Abstract][Full Text] [Related]
30. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459 [TBL] [Abstract][Full Text] [Related]
31. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109 [TBL] [Abstract][Full Text] [Related]
32. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649 [TBL] [Abstract][Full Text] [Related]
33. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801 [TBL] [Abstract][Full Text] [Related]
34. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339 [TBL] [Abstract][Full Text] [Related]
35. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related]
36. Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis. Navarria P; Pessina F; Cozzi L; Tomatis S; Reggiori G; Simonelli M; Santoro A; Clerici E; Franzese C; Carta G; Conti Nibali M; Bello L; Scorsetti M Tumori; 2019 Feb; 105(1):47-54. PubMed ID: 30131010 [TBL] [Abstract][Full Text] [Related]
37. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis. Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891 [TBL] [Abstract][Full Text] [Related]
38. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157 [TBL] [Abstract][Full Text] [Related]
39. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550 [TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide. Younis SG; Khedr RA; El-Shorbagy SH J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]